About Us
Vice Chairwoman of the Board, Executive Director: Ms. Cheng Cheung Ling
-
- Vice Chairwoman of the Board, Executive Director: Ms. Cheng Cheung Ling
- One of the founders of the Company, she is currently the Vice Chairwoman of the Board, an Executive Director, and a member of the Executive Board Committee. Ms. Cheng was born in 1964, graduated from the Guanghua School of Management at Peking University with an Master Degree in Business Administration. She is also a clinician. She has extensive experience and a unique vision in the management and investment of the pharmaceutical industry, and spares no effort in promoting industry transformation and innovation, strengthening R&D, and expanding international cooperation. As the founder of Beijing Tide Pharmaceutical, Ms. Zheng, with her unique insight of "Focusing on Innovation to Achieve Leapfrog Development for the Enterprise", has led Beijing Tide Pharmaceutical to commit to innovation in all aspects including R&D, production, marketing, and management, and to vigorously expand international cooperation to promote the rapid development of the high-end medical industry in China. Under her leadership, Beijing Tide Pharmaceutical has achieved transformative development through internationalization and innovation, becoming a leading domestic enterprise in the R&D, production, and sales of targeted drugs, and has been ranked on the "Top 100 Chinese Pharmaceutical Companies" list for many years.
For many years, Ms. Zheng has been dedicated to promoting personnel exchanges and economic and trade ties between Mainland China and Hong Kong, doing a great deal of work to foster national sentiment and promote bilateral cooperation. At the same time, she is enthusiastic about public welfare and actively participates in and cares about social charitable causes. Ms. Zheng also holds several public positions, including: Founding President of the Hong Kong Chinese Friendship Association, Founding President of the Hong Kong Belt and Road General Chamber of Commerce, former Chairwoman of the Friendship Association of Hong Kong Provincial CPPCC Members, and Convener of the Standing Committee of the 8th, 9th, 10th, 11th, 12th, and 13th Shaanxi Provincial Committee of the CPPCC.
Ms. Zheng's outstanding contributions to social services have been recognized by all sectors—she was appointed a Justice of the Peace (JP) by the Hong Kong SAR Government and was awarded the Silver Bauhinia Star (SBS) by the SAR Government. She has also been successively granted honors by various organizations, including the 4th Beijing "Jinghua Award", the 11th Qingdao "Qindao Award", "Advanced Individual in the Fight Against the COVID-19 Pandemic in 2020", "Pioneering Figure of the Year in China's Pharmaceutical Industry" for 2019 and 2020, and "Top Ten Leading Figures in China's Economy in 2019".
-
"2025 Science and Technology + New Quality Productive Forces Summit" Held in Hong Kong, Attended by Ms. Cheng Cheung Ling and Mr. Eric Tse Who Delivered Speeches 2025.12
On December 16, the "2025 Science and Technology + New Quality Productive Forces Summit", organized by the Hong Kong China Friendship Association, was held in Hong Kong.View > -
Sino Biopharm Donates HK$10 Million in Cash and Medicine for Emergency Relief of Tai Po Fire in Hong Kong 2025.11
On November 26, a sudden fire broke out at Wang Fuk Court in Tai Po District, New Territories, Hong Kong, drawing concern from across the nation.View > -
Senior Chairman of Charoen Pokphand Group Mr. Dhanin Chearavanont Attended the 80th Anniversary of the Victory in the Chinese People's War of Resistance, Leaders of CP Pharmaceutical Group Were Invited to Observe the Ceremony 2025.09
On the morning of September 3, a grand ceremony commemorating the 80th anniversary of the victory in the Chinese People's War of Resistance Against Japanese Aggression and the World Anti-Fascist War was held in Tiananmen Square, Beijing.View > -
Sino Biopharm Reports Strong H1 Results: Net Profit Doubles, Innovation Drives Record Revenue of RMB 17.57 Billion 2025.08
On the afternoon of August 18, Sino Biopharm (1177.HK) held its interim results conference in Hong Kong, continuing its outstanding performance of high growth in revenue and net profit: In the first half of 2025, the company's revenue reached RMB 17.57 billion, with a year-on-year increase of 10.7%; the net profit attributable to owners of the parent from continuing operations was RMB 3.39 billion, with a substantial increase of 140.2%; and the adjusted net profit attributable to owners of the parent was RMB 3.09 billion, with a year-on-year increase of 101.1%.View >